HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.
3rd Edition of
International Ophthalmology Conference
March 10-12, 2025 | Rome, Italy
Dry Eye Infographic/Dry Eye Syndrome
Dry Eye Infographic/Dry Eye Syndrome
A prolonged absence of lubrication and moisture on the surface of the eye causes dry eyes. To maintain your eyes healthy, comfortable, and seeing well, you need an adequate and regular layer of tears on the surface of the eye. The condition of having dry eyes is known as dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS). Dry eyes can cause a variety of symptoms, ranging from minor irritation to severe inflammation. It may also result in scarring on the eye's front surface. Dry eye syndrome is a frequent ocular condition. Depending on the demographic studied, it affects 5–34 percent of persons to some degree.
- Eye Infographic
- Contact Lens
- Diagnosis and Pathophysiology
- Artificial Tears and Other Treatments
Committee Members
John David Bullock
Wright State University, United States
Edward Charles Kondrot
Healing the Eye Wellness Center, United States
Minckler Don S
UCI Gavin Herbert Eye Institute, United States IOC 2025 Speakers
Dhruva Drew Gupta
Harvard Medical School, United States
Nour Abou Shousha
Harvard Medical School, United States
George HH Beiko
McMaster Univeresity, Canada
Mustafa Al Ghazi
University Hospital of Wales, United KingdomSubmit your abstract Today
Title : Optic nerve orthograde axonal transport in abusive head trauma suspects
Minckler Don S, UCI Gavin Herbert Eye Institute, United States
Title : Eyes and guts connection: Microbiomes and their role in ocular health
Edward Charles Kondrot, Healing the Eye Wellness Center, United States
Title : Why was Leonhard Euler blind?
John David Bullock, Wright State University, United States
Title : Ultra-widefield protocol enhances automated classification of diabetic retinopathy severity with OCT angiography
Kasra Rezaei, University of Washington, United States
Title : A factorial randomized controlled trial of tissue plasminogen activator and/or perfluoropropane for the treatment of submacular hemorrhage secondary to neovascular age-related macular degeneration (TAPAS)
Tim Jackson, King’s College London, United Kingdom
Title : Developing resilience-based treatments for glaucoma
Simon John, Columbia University, United States